KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the closing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. In addition, the Company announced today that it closed the sale of an additional 1,598,000 shares of common stock pursuant to the partial exercise of the option to purchase additional shares by the underwriters of the public offering. With this exercise, the Company has sold 12,848,000 shares in this offering, representing net proceeds of approximately $47.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Trevena.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
